IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis
Abstract Background Methotrexate (MTX) is the standard first-line therapy in rheumatoid arthritis (RA) with variable clinical efficacy that is difficult to predict. The glycosylation status of immunoglobulin G (IgG) is altered in RA and influenced by MTX treatment. We aimed to further investigate if...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2017-08-01
|
| Rangatū: | Arthritis Research & Therapy |
| Ngā marau: | |
| Urunga tuihono: | http://link.springer.com/article/10.1186/s13075-017-1389-7 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|